{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:11:45Z","timestamp":1789755105110,"version":"4.0.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAPES-PrInt Program","award":["88887.886709\/2023-00"],"award-info":[{"award-number":["88887.886709\/2023-00"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Non-receptor Tyrosine kinase inhibitors (TKIs), such as ABL1 and JAK inhibitors, are central to the management of classical myeloproliferative neoplasms (MPNs), yet non-adherence remains frequent and is associated with poorer clinical outcomes. Although adherence-related factors have been explored, the evidence has not been systematically synthesised within a behavioural theory framework to guide the development of effective interventions. This review aims to synthesise evidence on modifiable determinants (barriers and facilitators) influencing adherence to TKI therapy in adults with classical MPNs, and to classify these determinants using the Theoretical Domains Framework (TDF) and Capability, Opportunity, Motivation-Behaviour (COM-B) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a mixed-methods systematic review protocol. We will search MEDLINE\/PubMed, Embase, CINAHL, LILACS, PsycINFO, and the Cochrane Library from inception to the present, without date restrictions, alongside grey literature sources (OpenGrey, WorldCat, and Google Scholar). Key terms will include myeloproliferative neoplasms, chronic myeloid leukaemia, polycythaemia vera, primary myelofibrosis, tyrosine kinase inhibitors, imatinib, dasatinib, ruxolitinib, and medication adherence. Two reviewers will independently screen studies, extract data, and assess methodological quality using design-appropriate appraisal tools. Quantitative findings will be synthesised narratively and meta-analysed where appropriate. Effect estimates from quantitative studies and qualitative findings (including participant quotations and interpretative data) will be mapped to TDF domains and COM-B components. A mixed-methods synthesis will integrate and triangulate determinants across study designs. Confidence in the evidence will be assessed using GRADE (quantitative) and CERQual (qualitative).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review will provide a theory-informed synthesis of modifiable determinants of TKI adherence in classical MPNs, supporting the identification of targets for future adherence-enhancing interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Systematic review registration:<\/jats:bold>\n                      PROSPERO registration number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/CRD42024512635\" xlink:type=\"simple\">CRD42024512635<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0358485","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:51:02Z","timestamp":1789753862000},"page":"e0358485","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-7014","authenticated-orcid":true,"given":"Fabiana Coelho","family":"Inouye","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo","place":["Ribeir\u00e3o Preto, Brazil"]},{"name":"Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3054-9822","authenticated-orcid":true,"given":"Vivien","family":"Teo","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Clarke","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-9985","authenticated-orcid":true,"given":"Sofia","family":"Georgopoulou","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King\u2019s College London","place":["London, United Kingdom"]},{"name":"Applied Health Research Group, The Royal Marsden NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria Rosa","family":"Freato Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo","place":["Ribeir\u00e3o Preto, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena L\u00f4bo","family":"de Figueiredo-Pontes","sequence":"additional","affiliation":[{"name":"Hematology, and Clinical Oncology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo","place":["Ribeir\u00e3o Preto, Brazil"],"department":["Department of Medical Imaging"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"R\u00e9gis Leira Pereira","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo","place":["Ribeir\u00e3o Preto, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chapman","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"pone.0358485.ref001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"NP Shah","year":"2024","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"6","key":"pone.0358485.ref002","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/10781552221082293","article-title":"Management of Myeloproliferative Neoplasms (MPNs)","volume":"28","author":"Z Nurgat","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"pone.0358485.ref003","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"DA Arber","year":"2022","journal-title":"Blood"},{"key":"pone.0358485.ref004","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/cancers13040798","article-title":"Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia","volume":"13","author":"M Suttorp","year":"2021","journal-title":"Cancers"},{"key":"pone.0358485.ref005","unstructured":"Weltgesundheitsorganisation. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. Lyon: International Agency for Research on Cancer; 2017."},{"key":"pone.0358485.ref006","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"AT Gerds","year":"2022","journal-title":"J National Comprehensive Cancer Network"},{"issue":"4","key":"pone.0358485.ref007","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"A Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"pone.0358485.ref008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2021.1969388","article-title":"Adherence to ruxolitinib, an oral JAK1\/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)","volume":"63","author":"P Guglielmelli","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"pone.0358485.ref009","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"E Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"pone.0358485.ref010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"G Wei","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"14","key":"pone.0358485.ref011","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0358485.ref012","volume-title":"Adherence to long-term therapies: evidence for action","author":"E Sabat\u00e9","year":"2003"},{"key":"pone.0358485.ref013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5001\/omj.2011.38","article-title":"Patient medication adherence: measures in daily practice","volume":"26","author":"B Jimmy","year":"2011","journal-title":"Oman Med J"},{"key":"pone.0358485.ref014","unstructured":"National Collaborating Centre for Primary Care (UK). Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence [Internet]. London: Royal College of General Practitioners (UK); 2009 [cited 2026 Feb 23]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK55440\/. Accessed 23 Feb 2026."},{"issue":"7","key":"pone.0358485.ref015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1017\/S0033291721001446","article-title":"Mapping modifiable determinants of medication adherence in bipolar disorder (BD) to the theoretical domains framework (TDF): a systematic review","volume":"51","author":"AR Prajapati","year":"2021","journal-title":"Psychol Med"},{"issue":"2","key":"pone.0358485.ref016","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000011","article-title":"Interventions for helping patients to follow prescriptions for medications","author":"RB Haynes","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0358485.ref017","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s44411-025-00227-0","article-title":"Medication adherence and intervention strategies: why should we care","volume":"126","author":"P Schnorrerova","year":"2025","journal-title":"Bratisl Med J"},{"issue":"1","key":"pone.0358485.ref018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/opo.13245","article-title":"Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework","volume":"44","author":"D Bott","year":"2024","journal-title":"Ophthalmic Physiol Opt"},{"issue":"1","key":"pone.0358485.ref019","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13012-017-0605-9","article-title":"A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems","volume":"12","author":"L Atkins","year":"2017","journal-title":"Implement Sci"},{"key":"pone.0358485.ref020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1748-5908-7-37","article-title":"Validation of the theoretical domains framework for use in behaviour change and implementation research","volume":"7","author":"J Cane","year":"2012","journal-title":"Implement Sci"},{"issue":"4","key":"pone.0358485.ref021","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1464-0597.2008.00341.x","article-title":"From Theory to Intervention: Mapping Theoretically Derived Behavioural Determinants to Behaviour Change Techniques","volume":"57","author":"S Michie","year":"2008","journal-title":"Applied Psychology"},{"key":"pone.0358485.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26633\/RPSP.2022.112","article-title":"A declara\u00e7\u00e3o PRISMA 2020: diretriz atualizada para relatar revis\u00f5es sistem\u00e1ticas","volume":"46","author":"MJ Page","year":"2022","journal-title":"Revista Panamericana de Salud P\u00fablica"},{"issue":"1","key":"pone.0358485.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"D Moher","year":"2015","journal-title":"Syst Rev"},{"key":"pone.0358485.ref024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2288-12-181","article-title":"Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ","volume":"12","author":"A Tong","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"pone.0358485.ref025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jha2.954","article-title":"Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis","volume":"5","author":"MR Grunwald","year":"2024","journal-title":"EJHaem"},{"key":"pone.0358485.ref026","volume-title":"Tyrosine Kinase Inhibitors. StatPearls [Internet]. Treasure Island (FL","author":"RJ Thomson","year":"2025"},{"issue":"5","key":"pone.0358485.ref027","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"MH Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"pone.0358485.ref028","author":"JPT Higgins"},{"issue":"1","key":"pone.0358485.ref029","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"M Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"2","key":"pone.0358485.ref030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2307\/2529786","article-title":"An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers","volume":"33","author":"JR Landis","year":"1977","journal-title":"Biometrics"},{"key":"pone.0358485.ref031","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"pone.0358485.ref032","doi-asserted-by":"crossref","first-page":"441","DOI":"10.11124\/JBIES-24-00103","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies","volume":"23","author":"TH Barker","year":"2025","journal-title":"JBI Evid Synth"},{"key":"pone.0358485.ref033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better","volume":"7","author":"L-L Ma","year":"2020","journal-title":"Military Med Res"},{"key":"pone.0358485.ref034","unstructured":"Critical Appraisal Skills Programme. CASP Checklist: CASP Qualitative Studies Checklist [Internet]. 2023.[cited 2026 Feb 23]. https:\/\/casp-uk.net\/casp-tools-checklists\/qualitative-studies-checklist\/. Accessed 23 Feb 2026."},{"key":"pone.0358485.ref035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.03.008","article-title":"Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study","volume":"111","author":"QN Hong","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7454","key":"pone.0358485.ref036","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"D Atkins","year":"2004","journal-title":"BMJ"},{"issue":"10","key":"pone.0358485.ref037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001895","article-title":"Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual)","volume":"12","author":"S Lewin","year":"2015","journal-title":"PLoS Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:51:08Z","timestamp":1789753868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358485"}},"subtitle":[],"editor":[{"given":"Claude","family":"Prigent","sequence":"first","affiliation":[{"name":"Centre de Recherche en Biologie cellulaire de Montpellier","place":["FRANCE"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358485","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}